NRx Pharma rises as DSMB finds depression drug 'safe'

NRX Pharmaceuticals

02/02/2023 14:12

** Shares of drug developer NRx Pharmaceuticals Inc  NRXP.O 
rise 3.4% to $1.22 premarket   
    **  Co says an independent Data Safety Monitoring Board
(DSMB) of the U.S. National Institutes of Health reviewed data
from an ongoing mid-stage study of its drug to potentially treat
severe bipolar depression and suicidal tendency 
    ** Says DSMB did not find any drug-related safety issues or
serious adverse events from the data and greenlights continued
enrollment for the trial  
    ** NRXP expects DSMB to examine unblinded study data for the
drug, NRX-101, in March this year
    ** Stock has fallen ~63.5% over the past 12 months
 (Reporting by Mariam E Sunny)
 ((Mariam.ESunny@thomsonreuters.com;))